AN2 Therapeutics Inc (ANTX)
2.165
-0.06
(-2.91%)
USD |
NASDAQ |
May 21, 16:00
2.165
0.00 (0.00%)
Pre-Market: 20:00
AN2 Therapeutics Research and Development Expense (Quarterly): 14.66M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.66M |
| December 31, 2023 | 14.92M |
| September 30, 2023 | 14.43M |
| June 30, 2023 | 13.54M |
| March 31, 2023 | 11.98M |
| December 31, 2022 | 8.752M |
| September 30, 2022 | 8.428M |
| Date | Value |
|---|---|
| June 30, 2022 | 6.698M |
| March 31, 2022 | 5.633M |
| December 31, 2021 | 5.812M |
| September 30, 2021 | 5.345M |
| June 30, 2021 | 4.10M |
| March 31, 2021 | 1.649M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.649M
Minimum
Mar 2021
14.92M
Maximum
Dec 2023
8.919M
Average
8.428M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Revance Therapeutics Inc | 14.39M |
| Viking Therapeutics Inc | 24.10M |
| VYNE Therapeutics Inc | 3.708M |
| Aquestive Therapeutics Inc | 5.932M |
| Humacyte Inc | 21.26M |